LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford lung study for chronic obstructive pulmonary disease, in collaboration with Innoviva Inc. (INVA), has had positive headline results.

The FTSE-100 healthcare company said the study showed that Relvar Ellipta achieved a superior reduction in exacerbations, compared with the usual care, in patients with COPD in an everyday clinical-practice setting. Study analyses are ongoing, the company said.

Shares at 1000 GMT up 5.50 pence, or 0.4%, at 1443.50 pence valuing the company at 70.32 billion pounds ($101.94 billion).

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

May 24, 2016 06:27 ET (10:27 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.